The term of agreement.

No definition available.

Name:	acrs_AgreementTermDuration
Namespace Prefix:	acrs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The fair value of consideration related to asset acquisition.

+ References

No definition available.

+ Details

Name:	acrs_AssetAcquisitionFairValueOfConsideration
Namespace Prefix:	acrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

In a business combination, the maximum contingent consideration to be paid based upon achievement of certain milestones as set forth in the Agreement and Plan of Merger.

+ References

No definition available.

+ Details

Name:	acrs_BusinessCombinationMaximumContingentConsiderationMilestonePaymentsPerAgreement
Namespace Prefix:	acrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The value of contingent consideration to be payable upon achievement of certain milestones.

+ References

No definition available.

+ Details

Name:	acrs_ContingentConsiderationPayableUponAchievementOfCertainMilestones
Namespace Prefix:	acrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The value of development costs and drug product materials to be reimbursed.

+ References

No definition available.

+ Details

Name:	acrs_CostsToBeReimbursed
Namespace Prefix:	acrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of development costs reimbursed during the period.

+ References

No definition available.

+ Details

Name:	acrs_DevelopmentCostsReimbursed
Namespace Prefix:	acrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of fair value of warrants issued in connection with in-license agreement.

+ References

No definition available.

+ Details

Name:	acrs_FairValueOfWarrantsIssuedInConnectionWithInLicenseAgreement
Namespace Prefix:	acrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of licensing fee receivable.

+ References

No definition available.

+ Details

Name:	acrs_LicensingFeeReceivable
Namespace Prefix:	acrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of cash outflow for payment of upfront consideration.

+ References

No definition available.

+ Details

Name:	acrs_PaymentOfUpfrontConsideration
Namespace Prefix:	acrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of sale of EPI Health cream.

+ References

No definition available.

+ Details

Name:	acrs_PercentageOfSaleOfEpiHealthCream
Namespace Prefix:	acrs_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash inflow associated with the amount received for regulatory and commercial milestones.

+ References

No definition available.

+ Details

Name:	acrs_RegulatoryAndCommercialMilestonesPaymentsReceived
Namespace Prefix:	acrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of transaction cost incurred as part of consideration transferred in asset acquisition.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 55
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479908/805-50-55-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480060/805-50-25-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-2

+ Details

Name:	us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 35
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479613/805-30-35-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479668/805-30-25-6

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

+ Details

Name:	us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=acrs_SunPharmaceuticalIndustriesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=acrs_PatentLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=acrs_EliLillyAndCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=acrs_AssetPurchaseAgreementEncompassingWorldwideRightsToOxymetazolineHydrochlorideCreamPlusIntellectualPropertyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=acrs_AgreementAndPlanOfMergerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=acrs_LicenseAndCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=acrs_AchievementOfSpecifiedRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=acrs_AchievementOfSpecifiedSalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Agreements Related to Intellectual Property (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended			12 Months Ended
	Nov. 30, 2024	Oct. 31, 2019	Aug. 31, 2017	Dec. 31, 2024	Dec. 31, 2023
Agreements Related to Intellectual Property
Estimated fair value				$ 44,845
Contingent consideration				8,700	$ 6,200
License Agreement \| Sun Pharmaceutical Industries, Inc
Agreements Related to Intellectual Property
Regulatory and commercial milestones				3,000	15,000
Non-Exclusive Patent License Agreement \| Eli Lilly and Company
Agreements Related to Intellectual Property
Regulatory and commercial milestones				13,200	$ 12,700
Licensing fee receivable				8,600
Asset Purchase Agreement
Agreements Related to Intellectual Property
Percentage of Sale of EPI Health Cream		1.00%
Agreement and Plan of Merger - Confluence
Agreements Related to Intellectual Property
Additional contingent consideration based on milestones, maximum, per Agreement			$ 75,000
Term of agreement			10 years
License and Collaboration Agreement
Agreements Related to Intellectual Property
Upfront cash amount	$ 30,000
Development costs of reimbursement	4,500
Costs to be reimbursed	$ 6,200
Consideration expensed				85,600
Incurred expensed				$ 1,300
Initial exercise price	$ 0.00001			$ 0.00001
Estimated fair value	$ 44,800			$ 44,800
License and Collaboration Agreement \| Achievement Of Specified Regulatory Milestones
Agreements Related to Intellectual Property
Achievement of specified regulatory milestones	125,000
License and Collaboration Agreement \| Achievement Of Specified Sales Milestones
Agreements Related to Intellectual Property
Achievement of specified regulatory milestones	$ 795,000